Clinical Trials: Lymphomas

Muscle Shoals : Northwest Alabama Cancer Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Beverly Hills : Tower Cancer Research Foundation

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.

Burbank : Providence Saint Joseph Medical Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Duarte : City of Hope Updated

A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently with Multi-Agent Chemotherapy as Front-Line Treatment in Patients with Systemic Anaplastic Large Cell Lymphoma

Duarte : City of Hope Updated

A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination with G- CSF to Mobilize and Collect >=5 x 106 CD34+ cells/kg in <=4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients with Non-Hodgkin's Lymphoma Weighing <=70 kg

Duarte : City of Hope Updated

A Phase I/II Study of VELCADE in Combination with Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma

Duarte : City of Hope Updated

Low-Dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

Fountain Valley : St. Joseph Mercy Hospital

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Loma Linda : Loma Linda U Cancer Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Rancho Mirage : Desert Hematology Oncology Medical Group

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Santa Monica : John Wayne Cancer Institute

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

View More »

La Jolla : Moores University of California San Diego Cancer Center

Safety and PK Study of RRx-001 in Cancer Subjects

Denver : Rocky Mountain Cancer Centers

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.

Southington : Cancer Center of Central Connecticut

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Ocala : Ocala Cancer Institute

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Marietta : Northwest Georgia Oncology Centers PC

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Savannah : Memorial Health University Medical Center

Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma SWOG 8947

Savannah : Memorial Health University Medical Center

Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes CALGB 9665

Savannah : Memorial Health University Medical Center

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma COG ANHL04B1

Savannah : Memorial Health University Medical Center

Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma SWOG 8819

Centralia : Southern Illinois Hematology Oncology

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Skokie : Clintell, Inc.

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

New Albany : Cancer Care Center Inc

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Sioux City : Siouxland Hematology Oncology Associates

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Hutchinson : Hutchinson Clinic

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Baltimore : Sidney Kimmel Comprehensive Cancer Center

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

Baltimore : The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

Boston : Novartis Investigative Site

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Ann Arbor : St. Joseph Mercy Hospital

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

St. Joseph : St. Joseph Oncology Inc.

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Lincoln : Nebraska Hematology/Oncology

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

North Platte : Great Plains Regional Medical Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Lebanon : Dartmouth Hitchcock Medical Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Bronx : Einstein-Montefiore Institute for Clinical & Translational Research

Phase 2 Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell (PBSC) Transplant in Patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Multiple Myeloma Undergoing Limited Re-infusion of CD34+ Cells

New Hyde Park : Biomedical Research Alliance of New York

Lymphoma

New Hyde Park : Biomedical Research Alliance of New York

Mantle Cell Lymphoma

New York : Columbia University

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

New York : Georgetown University

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.

New York : Weill Medical College of Cornell University

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.

Valhalla : New York Medical College

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

View More »

New York : Novartis Investigative Site

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Philadelphia : Temple University

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Pittsburgh : Allegheny General Hospital

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Pittsburgh : Western Pennsylvania Cancer Institute

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Sioux Falls : Avera Cancer Institute

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Nashville : Novartis Investigative Site

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Nashville : Sarah Cannon Research Institute

Safety and PK Study of RRx-001 in Cancer Subjects

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Mantle Zone Lymphoma

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Central Nervous System Lymphoma

Houston : S. R. Burzynski Clinic

Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Lymphoma Of The Gastrointestinal Tract

Richardson : HOPE Oncology

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Ogden : Northern Utah Associates

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Huntington : Marshall University

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Morgantown : West Virginia University - Clinical Trials Research Unit

273-08-201: A Multi-center, Phase 2, Single-Arm, Open-label Exploratory Study of Individually Optimized Conditioning Using PK-directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma

Morgantown : West Virginia University - Clinical Trials Research Unit

BMTCTN-0701: Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Remission

Morgantown : West Virginia University - Clinical Trials Research Unit

C50604 - Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin's Lymphoma

Morgantown : West Virginia University - Clinical Trials Research Unit

ECOG 2408: A Three-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenolidomide/Rituxan in High Risk Follicular Lymphoma

Morgantown : West Virginia University - Clinical Trials Research Unit

MI-CP204: An Open-label, Ph1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD 19, in Adult Subjects with Relapsed or Refractory Advanced B-cell Malignancies.

Morgantown : West Virginia University - Clinical Trials Research Unit

OMB110918-A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment

Morgantown : West Virginia University - Clinical Trials Research Unit

S0816 - A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin's Lymphoma Using Early Interim FDG-PET Imaging

Madison : University of Wisconsin Madison

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.

Marshfield : Marshfield Clinic

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Montreal, Quebec : Jewish General Hospital

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma.

Lyon Cedex : Novartis Investigative Site

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Villejuif Cedex : Novartis Investigative Site

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Utrecht : Novartis Investigative Site

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma

Heto Ray : Auxilio Cancer Center

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Tiong Bahru : National Cancer Centre

A Study of Alisertib (MLN8237) in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas